SK3362004A3 - Polymorfy hydrochloridu clopidogrelu a ich použitie ako antitrombotických zlúčenín - Google Patents
Polymorfy hydrochloridu clopidogrelu a ich použitie ako antitrombotických zlúčenín Download PDFInfo
- Publication number
- SK3362004A3 SK3362004A3 SK336-2004A SK3362004A SK3362004A3 SK 3362004 A3 SK3362004 A3 SK 3362004A3 SK 3362004 A SK3362004 A SK 3362004A SK 3362004 A3 SK3362004 A3 SK 3362004A3
- Authority
- SK
- Slovakia
- Prior art keywords
- acetate
- thieno
- chlorophenyl
- methyl
- dihydro
- Prior art date
Links
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 title description 7
- XIHVAFJSGWDBGA-RSAXXLAASA-N methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate;hydrochloride Chemical compound Cl.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl XIHVAFJSGWDBGA-RSAXXLAASA-N 0.000 title description 7
- 229950010560 clopidogrel hydrochloride Drugs 0.000 title description 6
- 239000003146 anticoagulant agent Substances 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 150000004677 hydrates Chemical class 0.000 claims abstract description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 57
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 51
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 31
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- 239000000010 aprotic solvent Substances 0.000 claims description 16
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 14
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 239000003880 polar aprotic solvent Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- -1 6,7-dihydro-4 H -thieno [3,2-c] pyridin-5-yl Chemical group 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 3
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- IEMGWBMVQLVHEY-UHFFFAOYSA-N ethyl 2-(3-amino-6,7-dihydro-5h-cyclopenta[b]pyridin-7-yl)acetate Chemical compound NC1=CN=C2C(CC(=O)OCC)CCC2=C1 IEMGWBMVQLVHEY-UHFFFAOYSA-N 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 4
- QMXCTKPNQFJZGK-UHFFFAOYSA-N hydron;4,5,6,7-tetrahydrothieno[3,2-c]pyridine;chloride Chemical compound Cl.C1NCCC2=C1C=CS2 QMXCTKPNQFJZGK-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- 229950010477 clopidogrel hydrogen sulphate Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000001407 anti-thrombic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- FDEODCTUSIWGLK-UHFFFAOYSA-N hydrogen sulfate;hydron;methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Chemical compound OS(O)(=O)=O.C1CC=2SC=CC=2CN1C(C(=O)OC)C1=CC=CC=C1Cl FDEODCTUSIWGLK-UHFFFAOYSA-N 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0200438A HUP0200438A3 (en) | 2002-02-06 | 2002-02-06 | Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them |
| PCT/HU2002/000157 WO2003066637A1 (fr) | 2002-02-06 | 2002-12-20 | Polymorphes d'hydrochlorure de clopidogrel et utilisation de ceux-ci en tant que composes antithrombotiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK3362004A3 true SK3362004A3 (sk) | 2005-03-04 |
Family
ID=89980128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK336-2004A SK3362004A3 (sk) | 2002-02-06 | 2002-12-20 | Polymorfy hydrochloridu clopidogrelu a ich použitie ako antitrombotických zlúčenín |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050113406A1 (fr) |
| EP (1) | EP1474427A1 (fr) |
| JP (1) | JP2005522441A (fr) |
| KR (1) | KR20040079987A (fr) |
| AU (1) | AU2002353251A1 (fr) |
| BG (1) | BG108868A (fr) |
| CZ (1) | CZ2004901A3 (fr) |
| EA (1) | EA007119B1 (fr) |
| HR (1) | HRP20040741A2 (fr) |
| HU (1) | HUP0200438A3 (fr) |
| IS (1) | IS7385A (fr) |
| PL (1) | PL370038A1 (fr) |
| SK (1) | SK3362004A3 (fr) |
| WO (1) | WO2003066637A1 (fr) |
| YU (1) | YU69604A (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0321256D0 (en) * | 2003-09-11 | 2003-10-08 | Generics Uk Ltd | Novel crystalline compounds |
| EA008972B1 (ru) * | 2004-01-13 | 2007-10-26 | Зентива А.С. | Новые кристаллические формы гидробромида клопидогреля и способы их получения |
| WO2005104663A2 (fr) * | 2004-03-05 | 2005-11-10 | Ipca Laboratories Limited | Procede industriel de fabrication de sulfate d'hydrogene de clopidrogrel |
| CN1938319B (zh) * | 2004-04-09 | 2010-05-12 | 韩美药品株式会社 | 结晶氯吡格雷萘磺酸盐或其水合物、其制备方法及含其的药物组合物 |
| KR20070012675A (ko) * | 2004-04-20 | 2007-01-26 | 사노피-아벤티스 | 메틸(+)-(Ｓ)-α-(2-클로로페닐)-6,7-디히드로티에노[3,2-Ｃ]피리딘-5(4Ｈ) 아세테이트 히드로브로마이드, 클로피도그렐히드로브로마이드의 다형성 형태 |
| NZ551374A (en) * | 2004-04-20 | 2010-08-27 | Sanofi Aventis | Clopidogrel naphthalenedisulfonate salt and polymorphic forms thereof |
| WO2005117866A1 (fr) * | 2004-06-01 | 2005-12-15 | Ivax Pharmaceuticals S.R.O. | Hydrochlorure de clopidogrel amorphe et son utilisation en tant qu'antithrombotique |
| EP1674468A1 (fr) * | 2004-12-21 | 2006-06-28 | Ratiopharm GmbH | Polymorphes de l'hydrobromide de clopidogrel |
| EP1693375A1 (fr) * | 2005-02-21 | 2006-08-23 | KRKA, tovarna zdravil, d.d., Novo mesto | Procédé pour la préparation de Clopidrogel hydrogène sulfate forme I |
| WO2007029080A1 (fr) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Preparation de chlorhydrate de clopidogrel de forme i |
| WO2007029096A2 (fr) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Nouvelles formes polymorphes de chlorhydrate de clopidogrel |
| KR20070066518A (ko) * | 2005-12-22 | 2007-06-27 | 에스케이케미칼주식회사 | 고체상 반응을 이용한 (ｓ)-(＋)-클로피도그렐의 제조방법 |
| KR101235117B1 (ko) * | 2005-12-26 | 2013-02-20 | 에스케이케미칼주식회사 | 광학분리에 의한 (ｓ)-(＋)-클로피도그렐의 제조방법 |
| KR100742134B1 (ko) * | 2006-02-07 | 2007-07-24 | 경동제약 주식회사 | 결정성Ｓ-(+)-메틸-2-(2-클로로페닐)-2-(6,7-디히드로티에노[3,2-ｃ]피리딘-5(4Ｈ)-일)아세테이트·캄실레이트를 포함하는약학적 조성물 |
| WO2008004249A2 (fr) * | 2006-07-04 | 2008-01-10 | Msn Laboratories Limited | Procédé amélioré de préparation de clopidogrel et de ses sels pharmaceutiquement acceptables |
| US20100062066A1 (en) * | 2006-11-14 | 2010-03-11 | Acusphere, Inc | Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration |
| EP1970054A3 (fr) | 2007-03-14 | 2009-06-03 | Ranbaxy Laboratories Limited | Comprimés de clopidogrel |
| DK2152078T3 (da) | 2007-04-27 | 2021-02-08 | Cydex Pharmaceuticals Inc | Formuleringer indeholdende clopidogrel og sulfoalkylethercyclodextrin og anvendelsesfremgangsmåder |
| EP2155756B1 (fr) * | 2007-05-30 | 2015-08-05 | Wockhardt Limited | Procede d'elaboration de clopidogrel |
| EP2107061A1 (fr) | 2008-04-02 | 2009-10-07 | Krka Tovarna Zdravil, D.D., Novo Mesto | Procédé de préparation de clopidogrel enrichi optiquement |
| DK3100728T3 (da) | 2009-05-13 | 2020-02-17 | Cydex Pharmaceuticals Inc | Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme |
| CN102120745B (zh) * | 2011-01-31 | 2013-04-10 | 天津红日药业股份有限公司 | 一种盐酸氯吡格雷的晶型ⅰ及其制备方法和用途 |
| WO2012123958A1 (fr) | 2011-02-14 | 2012-09-20 | Cadila Healthcare Limited | Sels très purs de clopidogrel exempts d'impuretés génotoxiques |
| CN102367257B (zh) * | 2011-11-21 | 2014-05-07 | 天津红日药业股份有限公司 | 氯吡格雷盐酸盐的单晶晶型，它们的制备及应用 |
| HUP1400294A2 (hu) | 2014-06-13 | 2015-12-28 | Skillpharm Kft | Clopidogrel új alkalmazása |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2530247B1 (fr) * | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| US5189170A (en) * | 1989-09-29 | 1993-02-23 | Sanofi | Process for the preparation of phenylacetic derivatives of thieno-pyridines |
| FR2664596B1 (fr) * | 1990-07-10 | 1994-06-10 | Sanofi Sa | Procede de preparation d'un derive n-phenylacetique de tetrahydrothieno [3,2-c] pyridine et son intermediaire de synthese. |
| HU225504B1 (en) * | 1997-05-13 | 2007-01-29 | Sanofi Aventis | Novel halophenyl-(2-(2-thienyl)-ethylamino)-acetonitriles and process for producing them |
| FR2779726B1 (fr) * | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
| HU226421B1 (en) * | 1998-11-09 | 2008-12-29 | Sanofi Aventis | Process for racemizing optically active 2-(2-chlorophenyl)-2-(2-(2-thienyl)-ethylamino)-acetamides |
-
2002
- 2002-02-06 HU HU0200438A patent/HUP0200438A3/hu unknown
- 2002-12-20 SK SK336-2004A patent/SK3362004A3/sk not_active Application Discontinuation
- 2002-12-20 WO PCT/HU2002/000157 patent/WO2003066637A1/fr not_active Application Discontinuation
- 2002-12-20 US US10/504,042 patent/US20050113406A1/en not_active Abandoned
- 2002-12-20 EP EP02788271A patent/EP1474427A1/fr not_active Withdrawn
- 2002-12-20 JP JP2003566010A patent/JP2005522441A/ja active Pending
- 2002-12-20 YU YU69604A patent/YU69604A/sh unknown
- 2002-12-20 AU AU2002353251A patent/AU2002353251A1/en not_active Abandoned
- 2002-12-20 CZ CZ2004901A patent/CZ2004901A3/cs unknown
- 2002-12-20 EA EA200401025A patent/EA007119B1/ru not_active IP Right Cessation
- 2002-12-20 KR KR10-2004-7012110A patent/KR20040079987A/ko not_active Application Discontinuation
- 2002-12-20 PL PL02370038A patent/PL370038A1/xx unknown
-
2004
- 2004-08-05 IS IS7385A patent/IS7385A/is unknown
- 2004-08-17 HR HRP20040741 patent/HRP20040741A2/xx not_active Application Discontinuation
- 2004-09-03 BG BG108868A patent/BG108868A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040079987A (ko) | 2004-09-16 |
| JP2005522441A (ja) | 2005-07-28 |
| HU0200438D0 (en) | 2002-04-29 |
| EA007119B1 (ru) | 2006-06-30 |
| YU69604A (sh) | 2006-08-17 |
| HUP0200438A3 (en) | 2003-10-28 |
| PL370038A1 (en) | 2005-05-16 |
| CZ2004901A3 (cs) | 2005-02-16 |
| WO2003066637A1 (fr) | 2003-08-14 |
| US20050113406A1 (en) | 2005-05-26 |
| HRP20040741A2 (en) | 2004-12-31 |
| BG108868A (en) | 2005-09-30 |
| HUP0200438A2 (hu) | 2003-09-29 |
| EP1474427A1 (fr) | 2004-11-10 |
| AU2002353251A1 (en) | 2003-09-02 |
| IS7385A (is) | 2004-08-05 |
| EA200401025A1 (ru) | 2004-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK3362004A3 (sk) | Polymorfy hydrochloridu clopidogrelu a ich použitie ako antitrombotických zlúčenín | |
| JP4494205B2 (ja) | カルシウム受容体調節化合物およびその用途 | |
| BG109361A (bg) | Нови полиморфни форми на оланзапин хидрохлорид | |
| SK2592003A3 (en) | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | |
| WO1996014319A1 (fr) | Derives de thienopyridine ou de thienopyrimidine et leur utilisation | |
| JPH09169768A (ja) | チエノピリミジン誘導体、その製造法および用途 | |
| KR20070012676A (ko) | 클로피도그렐 염 및 그의 다형성 형태 | |
| FI84604C (fi) | Foerfarande foer framstaellning av antipsykotiskt 8-/4-/4-(1-oxo-1,2-bensisotiazol-3-yl)-1-piperazinyl/butyl/ -8-azaspiro/4,5/dekan-7,9-dion eller salt daerav. | |
| EP1259515B1 (fr) | Derives de thienopyridine, leur production et leur utilisation | |
| WO1997040050A1 (fr) | Derives de la thienopyridine et leur utilisation | |
| JPH1036374A (ja) | チエノピリジン誘導体およびそれらを含んでなる医薬 | |
| KR20070023185A (ko) | Ｓ-(＋)-클로피도그렐 헤미나파디실레이트 염 및 그의제조방법 | |
| KR20050099445A (ko) | 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물 | |
| JPH1059977A (ja) | チエノピリジン誘導体およびそれらを含んでなる医薬 | |
| JPH08225577A (ja) | チエノピリジンまたはチエノピリミジン誘導体およびそれらを含んでなる医薬 | |
| WO2003042161A1 (fr) | Polymorphes de chlorhydrate de venlafaxine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |